Browsing All Christie Publications by Authors
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.Middleton, G; Silcocks, P; Cox, T; Valle, Juan W; Wadsley, J; Propper, D; Coxon, F; Ross, P; Madhusudan, S; Roques, T; et al. (2014-07)We aimed to assess the efficacy and safety of sequential or simultaneous telomerase vaccination (GV1001) in combination with chemotherapy in patients with locally advanced or metastatic pancreatic cancer.
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.Middleton, G; Palmer, D; Greenhalf, W; Ghaneh, P; Jackson, R; Cox, T; Evans, A; Shaw, V; Wadsley, J; Valle, Juan W; et al. (2017-03-01)Erlotinib is an EGFR tyrosine kinase inhibitor that has shown a significant but only marginally improved median overall survival when combined with gemcitabine in patients with locally advanced and metastatic pancreatic cancer. Vandetanib is a novel tyrosine kinase inhibitor of VEGFR2, RET, and EGFR, all of which are in involved in the pathogenesis of pancreatic cancer. We investigated the clinical efficacy of vandetanib when used in combination with gemcitabine in patients with advanced pancreatic cancer.